Navigation Links
Takeda San Francisco Enters Into A Sponsored Research Agreement With UCSF
Date:9/21/2009

SOUTH SAN FRANCISCO, Calif., Sept. 21 /PRNewswire/ -- Takeda San Francisco, Inc. (TSF), a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, announced today that it has entered into a sponsored research collaboration with the University of California, San Francisco. The research program will focus on therapeutic antibody discovery and development to an undisclosed target. The agreement will solely support specific research conducted in the laboratory of Charles Craik, Ph.D., who will serve as the principal investigator for the project. This agreement enhances TSF's initiative to build a robust preclinical antibody therapeutics pipeline by leveraging the company's comprehensive and proprietary antibody technology platform and novel discovery, optimization and development technologies.

"This partnership is another example of UCSF's increasing commitment to using its world-class biomedical research programs to bring direct benefit to patients," said Dr. Regis Kelly, Executive Director of QB3, the California Institute for Quantitative Biosciences, one of four California Institutes for Science and Innovation.

"We're pleased to work with Dr. Craik, who is a leader in the field of proteases associated with disease pathogenesis," said Dr. Mary Haak-Frendscho, President and CSO of TSF. "We believe this research will help enable the discovery and development of a novel antibody product candidate to preclinical proof of concept. It furthermore demonstrates our commitment to working with academic experts concerning the development of novel biologic targets for the treatment of disease."

About Takeda San Francisco, Inc.

Takeda San Francisco, Inc. (TSF), established in November 2007 as a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Osaka, Japan, is Takeda's Biologics Center of Excellence and Antibody IND Engine for human antibody t
'/>"/>

SOURCE Takeda San Francisco, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
2. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
3. Chemizon Announces Research Collaboration Expansion With Takeda
4. Takeda submits new drug application for alogliptin (syr-322) in the US
5. Takeda Announces New U.S. Leadership
6. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
7. Takeda Commences Cash Tender Offer for all Outstanding Shares of Millennium
8. Takeda Completes Acquisition of Millennium
9. Takedas investigational PPI TAK-390MR demonstrated higher healing rates compared to lansoprazole
10. FDA Adds Three Months to Review of Takedas New Drug Application for TAK-390MR
11. Review of Takedas Febuxostat New Drug Application Continues Past PDUFA Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... high-energy particles, simulating conditions astronauts would face on a ... slower reaction times, even when the radiation exposure is ... which affected a large subset, but far from ... to protein changes in the brain, the scientists say. ... suggest it may be possible to develop a biological ...
(Date:4/23/2014)... tract has long been considered to be between 180 ... have used refined microscopic techniques that indicate a much ... gastro-intestinal tract is only as large as a normal ... tract, which passes from the mouth through the esophagus ... about 5 meters in a normal adult, and is ...
(Date:4/23/2014)... American Gastroenterological Association (AGA) Research Foundation is pleased ... AGA Research Scholar Awards program, launched in 1984, ... research careers in digestive diseases. This year, the ... allowing for three consecutive years of funding. , ... are paving the way for promising research developments ...
(Date:4/23/2014)... 21, 2014 Five for-profit and non-profit organizations ... million in Proof of Concept grants to accelerate ... commercial products, the Life Sciences Discovery Fund (LSDF) ... Mentoring Program grant to the Washington Biotechnology & ... network to train the next generation of entrepreneurs ...
(Date:4/23/2014)... journal Oncotarget , explored tumour heterogeneity ... own DNA signatures within the same cancer. Such ... targeted treatment strategies. , Firstly they confirmed the ... the KRAS or BRAF mutation. Secondly, they found ... mutation have that specific mutation present uniformly throughout ...
Breaking Medicine News(10 mins):Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2Health News:AGA announces 2014 Class of AGA Research Scholars 2Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2
... fruit fly,s immune system can tell time, researchers at ... how hard it punches back against infections depends on ... could have implications for human health, too. , Working ... cycle and with syringes small enough to inject measured ...
... LLC will be featured in an upcoming episode. , ... Deerfield Beach, ... are pleased to announce that Gradient Medical, LLC will be featured in ... Tomorrow,s Health Solutions Today., , ,Pain is a national public healthcare crisis. ...
... of a breast cancer prevention study using exemestane (Aromasin) ... ongoing phase II study details reported today, by Jennifer ... Comprehensive Cancer Center at the San Antonio Breast Cancer ... who are at an increased risk of developing breast ...
... Expression of the microtubule-binding protein Tau is not a ... paclitaxel chemotherapy, according to research led by The University ... today, Dec. 13, at the CRTC-AACR San Antonio Breast ... predict survival, yet in an unexpected way. ...
... areas that show up light on a mammogram - ... "why" remains to be answered. Now, by examining dense ... volunteers, researchers from Mayo Clinic have found several potential ... poster form at the Cancer Therapy & Research Center-American ...
... the finish line in second place at the 2008 Ford Ironman ... for 34 year-old Jason Fowler, who was one of five wheelchair ... the Pacific Ocean, using only his arms, a 112-mile bike ride ... that Jason completed in a racing wheelchair in 90 degree heat. ...
Cached Medicine News:Health News:Snoring or soaring? Strength of fruit-fly immune system varies 2Health News:Snoring or soaring? Strength of fruit-fly immune system varies 3Health News:"The Economic Report" Show to Feature Gradient Medical, LLC 2Health News:Tau protein expression predicts breast cancer survival -- though not as expected 2Health News:Tau protein expression predicts breast cancer survival -- though not as expected 3Health News:Mayo researchers find potential links between breast density and breast cancer risk 2Health News:Mayo researchers find potential links between breast density and breast cancer risk 3Health News:Video: Paralyzed From the Chest Down, Triathlete Takes Second in the Handcycle Division of the Ford Ironman World Championship 2Health News:Video: Paralyzed From the Chest Down, Triathlete Takes Second in the Handcycle Division of the Ford Ironman World Championship 3Health News:Video: Paralyzed From the Chest Down, Triathlete Takes Second in the Handcycle Division of the Ford Ironman World Championship 4Health News:Video: Paralyzed From the Chest Down, Triathlete Takes Second in the Handcycle Division of the Ford Ironman World Championship 5
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, Inc ... of less invasive, miniaturized circulatory support technologies that are ... that it expects revenues for the fourth quarter of ... 2013 revenues to approximately $208 million. "Our ...
(Date:1/14/2014)... Jan. 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a ... it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... terms of the acquisition were not disclosed. ... providing a wide range of sleep, mobility, and respiratory products ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... has revolutionized healthcare and is essential in the detection ... protocols ensure that patients, physicians, and technicians are exposed ... providing accurate results and diagnostic information. ... be balanced with the benefits of that procedure. Alarmist ...
... Muscular Dystrophy Association ( MDA ) has awarded $750,000 to ... development of an experimental drug that may become a viable ... The funding comes from MDA Venture Philanthropy (MVP), ... is one of nine types of muscular dystrophy, a group ...
Cached Medicine Technology:AAPM Cautions that Patients Should Not Forgo Essential Medical Imaging 2MDA Awards $750,000 to Help Summit Test New Drug Formulation in Phase 1 Clinical Trial of Potential Treatment for Duchenne Muscular Dystrophy 2MDA Awards $750,000 to Help Summit Test New Drug Formulation in Phase 1 Clinical Trial of Potential Treatment for Duchenne Muscular Dystrophy 3MDA Awards $750,000 to Help Summit Test New Drug Formulation in Phase 1 Clinical Trial of Potential Treatment for Duchenne Muscular Dystrophy 4
Solid lower plate with outside width 28 mm. Open upper plate. Serrated handle with locking thumb screw and polished finish. Right....
Round solid lower plate. Open upper plate with inside diameter 15 mm. Serrated handle with locking thumb screw and polished finish. Most popular size or model....
Utrata-like fine angled tips with gently curved shaft for performing capsulorhexis through tunnel incisions. Dull finish. Flat handle....
This cross action forcep has delicate tips for grasping the capsule. The forcep has an iris stop to prevent inadvertent grasping of the iris....
Medicine Products: